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Abstract
Recent studies have reported the detection of the human neurotropic virus, JCV, in a significant population of brain tumors,
including medulloblastomas. Accordingly, expression of the JCV early protein, T-antigen, which has transforming activity in
cell culture and in transgenic mice, results in the development of a broad range of tumors of neural crest and glial origin.
Evidently, the association of T-antigen with a range of tumor-suppressor proteins, including p53 and pRb, and signaling
molecules, such as b-catenin and IRS-1, plays a role in the oncogenic function of JCV T-antigen. We demonstrate that T-
antigen expression is suppressed by glucose deprivation in medulloblastoma cells and in glioblastoma xenografts that both
endogenously express T-antigen. Mechanistic studies indicate that glucose deprivation-mediated suppression of T-antigen
is partly influenced by 59-activated AMP kinase (AMPK), an important sensor of the AMP/ATP ratio in cells. In addition,
glucose deprivation-induced cell cycle arrest in the G1 phase is blocked with AMPK inhibition, which also prevents T-antigen
downregulation. Furthermore, T-antigen prevents G1 arrest and sustains cells in the G2 phase during glucose deprivation.
On a functional level, T-antigen downregulation is partially dependent on reactive oxygen species (ROS) production during
glucose deprivation, and T-antigen prevents ROS induction, loss of ATP production, and cytotoxicity induced by glucose
deprivation. Additionally, we have found that T-antigen is downregulated by the glycolytic inhibitor, 2-deoxy-D-glucose (2-
DG), and the pentose phosphate inhibitors, 6-aminonicotinamide and oxythiamine, and that T-antigen modulates
expression of the glycolytic enzyme, hexokinase 2 (HK2), and the pentose phosphate enzyme, transaldolase-1 (TALDO1),
indicating a potential link between T-antigen and metabolic regulation. These studies point to the possible involvement of
JCV T-antigen in medulloblastoma proliferation and the metabolic phenotype and may enhance our understanding of the
role of viral proteins in glycolytic tumor metabolism, thus providing useful targets for the treatment of virus-induced
tumors.
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Introduction
JC virus (JCV) is the causative agent of the fatal human
demyelinating disease, progressive multifocal leukoencephalopathy
(PML), and has also been associated with multiple tumors of the
central nervous system, including astrocytomas, glioblastomas,
neuroblastomas, and medulloblastomas [1,2] These CNS tumors
can be marked by highly aggressive courses, with five-year
survivals ranging from 50% in less aggressive forms to just 4%
for patients with glioblastoma (Central Brain Tumor Registry of
the United States, CBTRUS). Though there are many ongoing
studies involved in the discovery of genetic factors underlying
malignant tumorigenesis, especially pathways involved in cell
survival and angiogenesis, there has been relatively limited
research pertaining to the role of oncogenic viruses in the
progression of solid tumors.
One of the key viral regulatory proteins of JCV, T-antigen, has
been shown to be associated with human brain tumor formation.
For example, JCV T-antigen protein expression can be detected
by immunohistochemistry in as many as 50% of human brain
tumors [1,3]. Furthermore, JCV T-antigen-mediated transforma-
tion is known to occur in cells of neural origin, further implicating
this oncogene in the pathogenesis of malignant brain tumors. On a
molecular level, cells expressing T-antigen exhibit properties of
immortalization, such as morphological changes, rapid doubling
time, anchorage-independent growth, and production of flank
tumors in nude mice [4]. Moreover, JCV T-antigen has been
shown to deregulate cell cycle machinery through binding and
inactivation of the tumor suppressors, p53 and pRb [5–7], and can
augment expression of c-myc through b-catenin and LEF-1 [8].
Though these studies have provided useful insight into the
transforming abilities of T-antigen, there have been few studies
examining the regulation of endogenous T-antigen expression in
brain tumors and the effect of tumoral physiological processes on
this expression. In addition, there have not been any studies
examining the effect of T-antigen on glycolysis or metabolic
pathways utilized during tumor pathogenesis.
Glucose metabolism regulates the growth of many solid tumors,
and the widely known observation that tumor cells exhibit much-
enhanced glycolytic rates to satisfy the need for increased ATP
demand, known as the Warburg effect [9], underlies much of a
tumor’s growth potential. Tumor cells also utilize glucose at an
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form of nicotinamide adenine dinucleotide (NADPH) and to limit
the production of reactive oxygen species (ROS). Therefore, we
investigated the effect of glucose deprivation on T-antigen
expression and cell cycle regulatory and metabolic control
mediated by T-antigen under these conditions. In this study, we
have found that JCV T-antigen is downregulated under conditions
of glucose deprivation in brain tumor-derived cell lines endoge-
nously expressing JCV T-antigen and that T-antigen interacts with
the 59-adenosine monophosphate (AMP)-activated protein kinase
(AMPK) pathway and exerts control over cell cycle and glucose
metabolic pathways. These findings expand our current knowl-
edge regarding mechanisms of T-antigen transformation and
implicate this oncogene in metabolic pathways underlying
tumorigenesis.
Methods
Cell Culture and Reagents
The human glioblastoma cell line, U-87MG, was obtained from
ATCC. The mouse medulloblastoma cell lines expressing T-
antigen, BsB8, as well as those not expressing T-antigen, Bs1a and
Bs1f, were previously described [2]. HJC-2 cells were derived from
glioblastomas generated in hamsters intracerebrally inoculated
with JCV [10] and are tumorigenic in vivo [11]. All cell lines used
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal bovine serum and 100 units/mL
penicillin and 100 ug/mL streptomycin. For experiments with
glucose deprivation, DMEM containing 10% dialyzed FBS and
either 1 g/L glucose or no glucose was utilized. All cells were
plated at exactly the same cell number and were of similar
confluence at the time of each experiment. Efforts were made to
treat each well exactly the same during washes and medium
changes to minimize intra-experimental variability. The construc-
tion of CMV-cyclin E was described previously [12]. N-
acetylcysteine (Sigma) was used at a final concentration of
24 mM, and pyruvate (Gibco) was used at a final concentration
of 1 mM. Fenofibrate (Sigma), 2-deoxy-D-glucose (Sigma), sodium
oxamate (Sigma), 6-aminonicotinamide (Cayman Chemical), and
oxythiamine (MP Biomedicals) were used at the indicated doses.
Construction of Adenoviral vector capable of expressing
JCV T-antigen
Cloning of an intronless JCV T-antigen [13] as a glutathione S-
transferase (GST) fusion protein in the pGEX2T plasmid was
described earlier [14]. Adenoviral vector construction was
performed by Dr. Satish Deshmane, using a commercially
available kit from Microbix Inc. (Ontario, Canada). JCV T-
antigen DNA coding sequences were PCR-amplified, digested
with EcoRI, and cloned into the EcoRI site of pDC515io, an
adenoviral shuttle plasmid with an MCMV promoter. Recombi-
nant clones were sequenced to confirm authenticity and proper
orientation. This recombinant plasmid and another plasmid
named pBHGfrt(del)E1,3FLP that provided an adenovirus type-
5 genomic-backbone with E1 and E3 gene deletion were further
used to co-transfect HEK 293 IQ cells. A recombinant adenovirus
generated as a result of site-specific recombination was isolated,
amplified, and further purified by cesium chloride density
equilibrium banding. The construction of Ad-Null, a control
adenovirus without any transgene, was described earlier [15].
Construction of JCV large T-antigen shRNA
The shRNA construct for large T-antigen was described
previously [16]. Briefly, shRNA constructs were generated to
target the nucleotide sequences 139 to 162 of the JCV large T-
antigen cDNA. PCR products carrying sense and antisense
oligonucleotides of large T-antigen were cloned into the pLL3.7
vector. The viruses were packaged in 293T (human embryonic
kidney) cells according to the procedure described previously.
HJC-2 cells were seeded in 6-well plates at 50% confluency and
were incubated with 1 mL of viral supernatants. The infected cells
were then incubated in regular complete medium (16 DMEM,
10% FBS) for 48 hours. Inspection by fluorescence microscopy
confirmed the presence of more than 80% of GFP-positive cells
after viral infection.
Cell Extraction and Western Blot Analysis
Whole-cell, cytoplasmic, nuclear protein extraction, and
western blot were performed as previously described [17].
Antibodies used were as follows: SV40 Large T-antigen (Calbio-
chem, pAb416), Phospho-AMPK (Thr172) (Cell Signal), AMPK
(Cell Signal), cyclin B1 (Santa Cruz), Cdc2 p34 (Santa Cruz),
cyclin E (Calbiochem), cyclin A (Santa Cruz), G6PDH (Sigma),
PKM2 (Cell Signal), TALDO1 (Cell Signal), and a-tubulin
(Sigma). Immunoblots were developed using the appropriate
secondary horseradish peroxidase-coupled antibodies and an
enhanced chemiluminescence plus (ECL) kit (Pierce).
ATP Measurement
ATP measurement was performed according to the manufac-
turer’s instructions (Roche). Briefly, cells were lysed and were then
incubated with a luciferase reagent, which converts D-luciferin,
ATP, and oxygen to oxyluciferin, AMP, diphosphate, carbon
dioxide, and light. Luciferase values were measured on a tube
luminometer (Zylux Corporation), and values were plotted on an
ATP standard curve to obtain the concentration of ATP within
cells. All values were normalized to total protein levels in each
sample, and each experiment was conducted in triplicate.
Immunocytochemistry and Immunohistochemistry
For immunocytochemical studies, cells were plated in chamber
slides and were then treated with glucose deprivation. Subse-
quently, cells were fixed in 4% formaldehyde in PBS for
15 minutes at room temperature. Cells were blocked in 5%
normal goat serum for 2 hours at room temperature before
staining with the appropriate primary antibodies overnight at 4uC.
Cells were incubated with 1:500 dilution of the appropriate
secondary antibody and were then mounted with Vectashield
mounting medium containing DAPI (Vector Laboratories). Cells
were then analyzed by fluorescence microscopy on a Nikon
Eclipse TE300 microscope with Slidebook 5 software (Intelligent
Imaging Innovations).
For immunohistochemical analysis, brains were fixed in 4%
buffered formalin, embedded in paraffin, and sectioned at 4 mm
for histological and immunohistochemical analysis. Sections were
deparaffinized in xylene and were rehydrated through successive
incubations in decreasing concentrations of ethanol. Light
microscopy was then performed on sections stained with
hematoxylin and eosin (H&E). For immunohistochemical analysis,
nonenzymatic antigen retrieval in citrate buffer was then
performed for all antibodies by heating the slides to 95uCi n
0.01 M citrate (pH 6.0) for 30 min. The sections were then rinsed
in water followed by PBS and incubated in methanol containing
6% H2O2 for 20 minutes to quench endogenous peroxidase.
Sections were then blocked using 5% normal goat serum and were
incubated with the appropriate primary antibodies overnight at
room temperature in a humidified chamber. Immunohistochem-
istry was then performed using the avidin–biotin–perioxidase
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(Vectastain Elite ABC-Peroxidase Kit, Vector Laboratories).
Images were acquired on an Olympus AX70 microscope with
cellSens Entry software (Olympus).
Cell Cycle Analysis
All detached or dead cells in the medium were collected, and
remaining cells were then trypsinized and collected. The cell cycle
distribution was measured using Guava Cell Cycle reagent (Guava
Technologies). The percentage of cells in each phase of the cell
cycle was calculated according to the manufacturer’s instructions.
Each experiment was conducted in triplicate.
Reactive Oxygen Species (ROS) Detection
Cells were plated in chamber slides in either control media or
glucose deprivation media as described above, washed, and then
labeled with 25 mM carboxy-H2-DCFDA for 30 minutes at 37uC
according to the manufacturer’s instructions (Molecular Probes).
In the presence of ROS, the reduced carboxy-DCFH is converted
to carboxy-DCF and fluoresces green. Cells were counterstained
with Hoechst 33342 dye during the last 5 minutes of incubation.
Cells were then mounted in warm buffer and analyzed by
fluorescence microscopy on a Nikon Eclipse TE300 microscope
with Slidebook 5 software (Intelligent Imaging Innovations). ROS
levels were calculated by measuring the pixel intensity in triplicate
images using Adobe Photoshop CS software (Adobe).
Measurement of Cell Viability
All detached or dead cells in medium were collected, and
remaining cells were then trypsinized and collected. Cell viability
was measured using Guava ViaCount reagent (Guava Technol-
ogies). The total number of cells as well as the total number of
viable cells was counted. Each experiment was conducted in
triplicate.
Nude Mouse Tumor Studies
All experiments were conducted in accordance with the Temple
University Institutional Care and Animal Use Committee
(IACUC). For intracranial tumor implantation, one-million
HJC-2 cells were implanted intracranially into the brains of nude
mice at the following stereotaxic coordinates relative to bregma:
21.5 posterior, +2.5 lateral, and a depth of 23.5. Animals were
weighed twice a week to monitor changes in weight and appetite.
Three weeks after injection, animals were euthanized, and brains
were sectioned at 400 mm in ice-cold sectioning buffer consisting of
Gey’s balanced salt solution, 15% D-glucose, 50 mg/mL genta-
mycin, and 50 mg/mL amphotericin-B. Following sectioning,
slices were kept in ice-cold sectioning buffer for 30 minutes. Slices
were then placed on microfilters (0.4 um Millicell-CM, Millipore,
Inc., Bedford, MA) in 6-well plates in 1 mL/well of slice culture
medium consisting of 25% OPTIMEM, 25% fetal bovine serum
(FBS), 50% Hanks Balanced Salt Solution (HBSS), 50 mg/mL
gentamycin, and 50 mg/mL amphotericin-B. After two days, slice
cultures were treated with glucose deprivation or control medium
for the indicated time points. Subsequently, tissue slices were snap-
frozen for whole-cell extraction or processed for histological
evaluation.
Statistical Analysis
All experiments were conducted in triplicate, and results were
analyzed using a two-tailed Student’s t-test where indicated.
Results with a p-value,0.05 were assigned statistical significance.
Results
JCV T-antigen is downregulated by glucose deprivation
in T-antigen-expressing cells
Since tumor cells utilize glucose at an increased rate and given
findings of glucose metabolic regulation by SV40 small t-antigen
[18] we investigated the effect of glucose deprivation on T-antigen
expression. For these studies, we used the mouse medulloblastoma
cell line, BsB8, which was isolated from medulloblastoma tumors
induced in transgenic mice expressing the JCV early region [2].
Using both western blot and immunocytochemistry for T-antigen,
we found that glucose deprivation significantly downregulated
endogenous T-antigen protein expression in these cells after 24-
hour treatment (Figure 1a, b, and e). We also observed decreased
expression of small t-antigen during glucose deprivation (data not
shown). We found similar results in HJC-2 cells, a cell line that was
isolated from glioblastoma tissue induced in hamsters which were
intracerebrally inoculated with JC virus (Figure 1c, d, and e). This
cell line provides a unique benefit in that the virus itself without
any prior genetic manipulation was able to transform cells and
induce brain tumor formation, further lending support for the
transformative properties of JCV. In BsB8 cells, this glucose
deprivation-mediated T-antigen downregulation was able to be
rescued by placing these cells into normal glucose-containing
medium (1 g/L glucose) for an additional 24 or 48 hours (Figure 1f
and g). Exposure to glucose deprivation for more than 48 hours
led to some degree of cell death in BsB8 and HJC-2 cells (data not
shown). In BsB8 cells, transcriptional studies using luciferase assays
demonstrated an approximately 2-fold decrease in the activity of
the JCV early promoter that controls T-antigen expression (data
not shown). Therefore, it appears that the substantial decrease in
T-antigen protein expression during glucose deprivation is a result
of post-transcriptional or post-translational processing. These
results indicate that T-antigen expression may be regulated by
pathways involved in glucose metabolism under various stress
conditions.
AMPK activation mediates T-antigen downregulation,
and T-antigen suppresses AMPK activation during
glucose deprivation
Since it is well known that glucose deprivation leads to an
increase in the [AMP]/[ATP] ratio and subsequent activation of
AMP-activated protein kinase (AMPK) [19], we investigated the
involvement of this pathway in glucose deprivation-mediated T-
antigen downregulation. We first demonstrated that BsB8 cells
exhibit a decreased level of ATP during glucose deprivation
(Figure 2a). We found that treatment of BsB8 cells with AICAR,
an activator of AMPK, resulted in significant T-antigen down-
regulation (Figure 2b and c). Additionally, treatment of these cells
with fenofibrate, a peroxisome proliferator-activated receptor
(PPAR)a agonist that also activates the AMPK pathway, resulted
in T-antigen downregulation (Figure 2d). Furthermore, we
demonstrated that treatment with a specific AMPK inhibitor,
Compound C [20], resulted in rescue of T-antigen expression
under glucose deprivation conditions (Figure 2e and f). These data
demonstrate that AMPK activation is required for T-antigen
downregulation during periods of low glucose and that activation
of AMPK is sufficient to decrease T-antigen expression. Since it
has been shown that SV40 T-antigen can induce AMPK
activation during periods of glucose starvation [18], we also
wanted to investigate the role of JCV T-antigen in glucose
deprivation-induced AMPK activation. For these studies, we used
BsB8 cells as well as the clones, Bs1a and Bs1f, which were derived
from the same original medulloblastoma tumor tissue but which
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identical to BsB8 cells with respect to the extent of their
tumorigenic activity, they provide a useful model to study the
impact of T-antigen expression on the metabolic phenotype as well
as potential reasons for the lack of T-antigen expression in these
cells. We found less phosphorylation of AMPK in BsB8 cells as
compared to Bs1a or Bs1f cells, indicating that T-antigen can
suppress activation of AMPK under periods of glucose deprivation
(Figure 2g). Alternatively, the time necessary to observe significant
AMPK phosphorylation may be prolonged in BsB8 relative to
Bs1a or Bs1f cells, indicating initial differential responses to cell
stress in these cell types. In order to determine whether T-antigen
protein can be downregulated by glucose deprivation in other cell
types, we confirmed decreased expression of T-antigen during
glucose deprivation by transducing U-87MG cells with an
adenovirus expressing either T-antigen or a null construct.
Similarly to cells endogenously expressing T-antigen, U-87MG
cells expressing T-antigen exhibited less AMPK phosphorylation
during glucose deprivation than null- or non-transduced controls
(Figure 2h). Though T-antigen may not be required for
transformation of these cells, T-antigen does clearly influence
the metabolic response to glucose deprivation in these cells.
Together, these findings indicate a potential negative feedback
loop between JCV T-antigen and AMPK activation during
glucose deprivation, a pathway that may regulate metabolic
utilization of glucose in T-antigen-positive tumors.
AMPK activation induces G1 and G2 cell cycle arrest and
reduced cyclin expression, which modulates cell cycle
phase-regulated T-antigen expression
The link between AMPK activation and cell cycle regulation
has been investigated in many studies involving tumor pathogen-
esis [21,22]. Specifically, it has been demonstrated that AMPK
activation results in decreased levels of cyclin A, cyclin B1 and
cyclin E, but these changes may depend on the particular method
of activation [23,24]. During glucose deprivation, we found that
BsB8 cells exhibit downregulation of cyclin B1 and Cdk1 but no
significant changes in the expression of cyclin A (Figure 3a).
AMPK activation using AICAR alone was able to mimic the
effects of glucose deprivation on cyclin regulation as well, with
similar downregulation of cyclin B1 and Cdk1 (Figure 3b).
Interestingly, AMPK inhibition during glucose deprivation using
Compound C, which prevented T-antigen downregulation, also
Figure 1. JCV T-antigen is downregulated by glucose deprivation in vitro. Endogenous JCV T-antigen expression was monitored in the cell
lines, BsB8 (A and B) and HJC-2 (C and D), after 24-hour glucose deprivation by both western blot and immunocytochemical detection of T-antigen. E.
Expression of T-antigen during conditions of glucose deprivation in the above cell lines was quantified. BsB8 cells were exposed to glucose
deprivation for 24 hours and were then exposed to a subsequent time-course of normal medium containing 1 g/L D-glucose, after which T-antigen
expression was measured by western blot (F) and immunocytochemistry (G). C, control; GD, glucose deprivation.
doi:10.1371/journal.pone.0035054.g001
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regulation also led to concomitant alterations in cell cycle phase
control. Whereas glucose-deprived cells exhibited arrest in the G1
phase and less G2 accumulation, AMPK inhibition prevented G1
arrest and caused increased G2 accumulation, which was
associated with T-antigen rescue (Figure 3d). Previous studies
have noted that polyomaviruses tend to preferentially arrest cells in
the G2 phase of the cell cycle in order to replicate [25], so AMPK
inhibition-mediated T-antigen rescue during glucose deprivation
would enhance T-antigen-induced proliferation under cell stress
conditions in the tumor microenvironment. BsB8 cells transfected
with cyclin E, which acts as an inducer of G1 arrest, also caused T-
antigen downregulation, indicating that conditions that favor G1
arrest result in reduction in T-antigen expression (Figure 3e).
T-antigen induces expression of cyclin B1 and leads to
enhanced G2 accumulation
Because T-antigen is downregulated by glucose deprivation,
which has been shown to induce G1 arrest, we sought to
determine the effect of T-antigen on cyclin expression and the
functional consequences on cell cycle distribution. For these
studies, we used the T-antigen-expressing BsB8 cells and the T-
antigen non-expressing cells, Bs1a and Bs1f, described above.
When we compared the cell cycle expression profile of these cells
under glucose deprivation, we found that BsB8 cells expressed
higher levels of cyclin B1 and cyclin A relative to Bs1a and Bs1f
cells (Figure 4a). Furthermore, when we compared the cell cycle
distribution of these cells under glucose deprivation, we found that
BsB8 cells were significantly more resistant to G1 arrest and
exhibited significantly higher percentages of cells in the G2 phase
Figure 2. T-antigen and AMPK exhibit reciprocal repression during glucose deprivation. A. BsB8 cells were treated with glucose
deprivation for 24 hours, and ATP levels were quantified. Results are presented as the concentration of ATP and are normalized to the total protein
content of each sample. The experiment was conducted in triplicate. B. BsB8 cells were treated with the indicated doses of the AMPK activating
agent, AICAR, for 24 hours, and T-antigen expression was measured by western blot. C. Quantification of T-antigen expression in B. (*, p,0.05). D.
BsB8 cells were treated with fenofibrate at the indicated doses for 24 hours, and T-antigen and phosphorylated AMPK levels were determined by
western blot. E. BsB8 cells were treated with various doses of the inhibitor of AMPK activation, Compound C, or DMSO, under conditions of glucose
deprivation for 24 hours, and T-antigen expression was measured by western blot. F. Quantification of T-antigen expression in E. G. Bs1a, Bs1f, and
BsB8 cells were exposed to glucose deprivation for 24 hours, and T-antigen expression and AMPK phosphorylation were measured by western blot.
H. U-87MG cells that were transduced with adenovirus expressing T-antigen, Null, or were non-transduced were exposed to glucose deprivation for
24 hours, and T-antigen and phosphorylated AMPK levels were measured by western blot. C, control; GD, glucose deprivation.
doi:10.1371/journal.pone.0035054.g002
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T-antigen maintains cells in the G2 phase of the cell cycle, even in
the midst of G1-arresting cell stress signals.
T-antigen reduces ROS accumulation, prevents
decreased ATP levels, and prevents cytotoxicity during
glucose deprivation
It is well known that glucose deprivation induces production of
reactive oxygen species (ROS) through decreased production of
NADPH, the reduced form of nicotinamide adenine dinucleotide
phosphate (NADP
+), and a loss of reductive potential in the cell
[26]. Therefore, we hypothesized that ROS production during
glucose deprivation may play a role in T-antigen downregulation.
Treatment of BsB8 cells with the thiol antioxidant, N-acetylcys-
teine (NAC), completely prevented T-antigen downregulation
from glucose deprivation (Figure 5a). However, treatment of these
cells with pyruvate, a weaker anti-oxidant than NAC which has
also been shown to act as an intracellular scavenger of ROS [27],
did not prevent T-antigen downregulation. These data demon-
strate that the induction of ROS during glucose deprivation may
be important for the observed decrease in T-antigen expression.
To examine the importance of T-antigen expression on ROS
production during glucose deprivation, we used BsB8 cells as well
as the T-antigen non-expressing clones, Bs1a and Bs1f. We found
that ROS production was significantly reduced during glucose
deprivation in BsB8 cells as compared to Bs1f cells (Figure 5b).
BsB8 cells did not exhibit any increase in ROS production during
glucose deprivation, and there was a general increase in ROS
production in Bs1a cells during glucose deprivation with the
difference between these cells and BsB8 cells in this condition
approaching statistical significance (p=0.05). These findings
suggest that T-antigen is able to prevent ROS accumulation that
would lead to subsequent cytotoxicity during glucose deprivation.
During glucose deprivation, cells produce decreased ATP as a
result of a reduction in glycolytic rates and subsequent decline in
intermediates to be used in the mitochondrial electron transport
chain. Therefore, we investigated whether T-antigen affects the
production of ATP during periods of glucose starvation. As
compared to Bs1a and Bs1f cells, which demonstrated a reduction
in ATP levels under conditions of low glucose, BsB8 cells were
more resistant to diminished ATP production (Figure 5d).
Furthermore, BsB8 cells produced significantly less ATP under
Figure 3. T-antigen downregulation during glucose deprivation is associated with AMPK-mediated cell cycle control. A. BsB8 cells
were exposed to glucose deprivation for 24 hours, and the expression of T-antigen and cell cycle regulators was monitored by western blot. B. BsB8
cells were exposed to the indicated doses of AICAR, and the expression of T-antigen and cell cycle regulators was measured by western blot. C. BsB8
cells were treated with 5 uM Compound C (CC) or DMSO (D) and exposed to glucose deprivation for 24 hours, and the expression of cell cycle
regulators was monitored by western blot. D. Cell cycle analysis using Guava cell cycle reagent was performed in cells from C. (*, p,0.05). E. BsB8 cells
were transfected with CMV-cyclin E or empty vector, and T-antigen expression was monitored by western blot. C, control; GD, glucose deprivation.
doi:10.1371/journal.pone.0035054.g003
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different metabolic phenotype, may be less dependent on ATP
production, and may utilize cellular energy stores in alternative
manners.
We next wanted to investigate the functional significance of
glucose deprivation on survival of cells expressing endogenous T-
antigen. Since glucose deprivation induces rapid cytotoxicity
because of the resulting lack of reductive capacity within the cell,
we investigated the impact of T-antigen expression on glucose
deprivation-induced cell death. We found that BsB8 cells exhibited
significantly less glucose deprivation-mediated cytotoxicity than
Bs1a or Bs1f cells (Figure 5e and f). BsB8 cells can survive under
theseperiodsforamuchlongeramountoftimethantheirT-antigen
non-expressing counterparts. BsB8 cells survive past the 48-hour
timepoint under conditions of glucose deprivation (data not shown),
whereas this condition is uniformly lethal to the Bs1a and Bs1f cell
lines. These results suggest that the presence of T-antigen during
glucose deprivation may be protective against rapid cell death,
potentially because of T-antigen-mediated alterations in energy
metabolism and ROS production under periods of cell stress.
T-antigen is downregulated through specific glycolytic
pathways during glucose deprivation and regulates the
glycolytic enzyme expression profile in medulloblastoma
cells
Given our findings of T-antigen downregulation by glucose
deprivation and functional implications for cell survival, we next
studied the regulation of T-antigen at the glycolytic level. For these
studies, we used inhibitors of several key glycolytic enzymes to
determine the role of glycolysis in the regulation of endogenous T-
antigen expression. Treatment of BsB8 cells with 2-deoxy-D-
glucose (2-DG), which inhibits glycolysis after initial phosphory-
lation by hexokinase, induced T-antigen downregulation in a dose-
dependent manner (Figure 6a). To further identify glycolytic
regulation of T-antigen, we used oxamate, an inhibitor of the
enzyme, lactate dehydrogenase. We did not observe any
appreciable changes in T-antigen expression at varying doses of
oxamate, indicating that T-antigen regulation likely occurs
upstream of lactate production (Figure 6b). In light of our findings
demonstrating T-antigen prevention of ROS production during
glucose deprivation, a process ameliorated by NADPH production
from pentose phosphate pathway activity, we used inhibitors of
this pathway to determine the T-antigen expression status with
pentose phosphate pathway inhibition. Treatment of BsB8 cells
with 6-aminonicotinamide (6-AN), an inhibitor of glucose 6-
phosphate dehydrogenase (G6PDH), the rate-limiting enzyme in
the pentose phosphate pathway, resulted in marked downregula-
tion of T-antigen in a dose-dependent manner (Figure 6c).
Similarly, inhibition of the transketolase enzyme, which catalyzes
the production of fructose 6-phosphate and glyceraldehyde 3-
phosphate from pentose phosphate intermediates, with oxythia-
mine resulted in T-antigen downregulation in a dose-dependent
manner (Figure 6d). Therefore, it appears that T-antigen
expression may be controlled through various metabolic pathways
that regulate glucose breakdown.
In order to investigate whether T-antigen affects glycolytic
metabolism in medulloblastoma cells, we compared the expression
of glycolytic enzymes in the T-antigen-expressing BsB8 cells to the
T-antigen non-expressing Bs1a and Bs1f cells during glucose
deprivation. While we found no changes in the expression of
G6PDH or the M2 isoform of pyruvate kinase (PKM2), which has
been implicated in tumor metabolism and proliferation [28], we
found significantly higher levels of transaldolase-1 (TALDO1)
expression in BsB8 cells as compared to Bs1a and Bs1f cells, under
control conditions as well as during glucose deprivation (Figure 6e).
In addition, we found that BsB8 cells exhibit increased expression
of hexokinase-2 (HK2) in control medium but do not exhibit HK2
upregulation, as occurs in Bs1a and Bs1f cells, during glucose
deprivation. We confirmed these results using the glioblastoma cell
line, HJC-2, and performed experiments using lentivirus express-
ing T-antigen shRNA, which has been shown previously to be
effective at reducing T-antigen expression in this cell line by
greater than 50% and has been shown to induce apoptosis at
72 hours post-transfection [16]. We transduced these cells with
lentivirus expressing large T-antigen shRNA or scrambled shRNA
or used wild-type cells. We then exposed these cells to 16 hours of
glucose deprivation before measuring expression levels of glyco-
lytic enzymes by western blot. In this paradigm, we found that cells
Figure 4. T-antigen prevents G1 arrest and preferentially arrests cells in the G2 phase in glucose-deprived cells. A. Bs1a, Bs1f, and BsB8
cells were treated with glucose deprivation or control medium for 16 hours and were subsequently processed for whole-cell protein extraction for
western blot analysis of cell cycle regulatory proteins. B. Identical samples from A. were processed for cell cycle analysis using Guava cell cycle
reagent. (*=control compared to GD, p,0.05; #=BsB8 compared to Bs1a and Bs1f cells, p,0.05). C, control; GD, glucose deprivation.
doi:10.1371/journal.pone.0035054.g004
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control medium, verifying that T-antigen positively regulates HK2
expression (Figure 6f). We did not observe a significant decrease in
PKM2 levels in cells treated with T-antigen shRNA, similar to
results obtained in BsB8 cells. The difference between the HJC-2
and BSB8 cells in regards to their levels of TALDO1 may actually
reflect lower endogenous levels in the T-antigen negative clones,
rather than higher TALDO1 levels in the BSB8 cells. However,
the overall trend in TALDO1 was similar in the HJC-2 versus the
BSB8 cells. Taken together, these results suggest that T-antigen-
mediated alterations in the expression of glycolytic enzymes may
lead to subsequent modulation of glycolytic flux within tumor cells.
T-antigen is downregulated by glucose deprivation in ex
vivo tumor slice cultures
JCV T-antigen is a potent oncogenic protein that can interact
with a variety of cellular proteins to promote tumorigenesis. In
light of our findings of T-antigen downregulation by glucose
deprivation, we examined the metabolic regulation of T-antigen in
a semi-in vivo system. For these studies, we used an ex vivo tumor
slice culture model with HJC-2 glioblastoma xenografts implanted
into the brains of nude mice. Following tumor growth, brain slices
containing tumor were prepared and were then grown in vitro.
Tumor slice cultures were then exposed to various time-courses of
glucose deprivation or rescue in normal medium before harvesting
for western blot or immunohistochemical analysis. To reinforce
our previous findings, we found that T-antigen is downregulated
by 1 hour and 8 hours of glucose deprivation only appreciably
after 24 hours of rescue in normal medium (1 g/L D-glucose)
(Figure 7a). We were also able to identify reduction in T-antigen
expression in HJC-2 tumor tissue exposed to 1 hour and 8 hours
glucose deprivation plus rescue (Figure 7b). The changing pattern
of T-antigen expression during the time course of GD and rescue
paradigm suggests that mechanisms controlling the regulation of
Figure 5. T-antigen prevents glucose deprivation-induced ROS production, reduction in ATP levels, and cytotoxicity. A. BsB8 cells
were incubated with 24 mM N-acetylcysteine (NAC), 1 mM pyruvate, or were untreated and then exposed to glucose deprivation or control medium
for 24 hours. Pyruvate was dissolved in a small volume of water and a negligible volume was added to the medium in each well. The expression of T-
antigen was assessed in whole-cell extracts. B. Bs1a, Bs1f, or BsB8 cells were exposed to glucose deprivation or control medium for 16 hours, and ROS
production was measured using the fluorescent dye, 25 mM carboxy-H2-DCFDA. Hoechst staining was also performed to label nuclei. C. ROS levels
were quantified by calculating the mean pixel intensity in triplicate images acquired. (*=control compared to GD, p,0.05; #=BsB8 compared to
Bs1f, p,0.05). D. Bs1a, Bs1f, or BsB8 cells were exposed to glucose deprivation for 16 hours, and ATP levels were then measured. The levels of ATP per
cell were measured and were normalized to the total protein present in each sample. E. Bs1a, Bs1f, or BsB8 cells were exposed to glucose deprivation
or control medium for 24 hours, and cell viability was measured using Guava ViaCount reagent. (*=control compared to GD, p,0.05; #=BsB8
compared to Bs1a and Bs1f cells, p,0.05). F. Phase-contrast images of cells treated with glucose deprivation in D. C, control; GD, glucose deprivation.
doi:10.1371/journal.pone.0035054.g005
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term effects and understanding these effects will require further
study. These data indicate that T-antigen is also downregulated by
glucose deprivation within tumor tissue and may provide useful
information to develop strategies against T-antigen-positive brain
tumors.
Discussion
JC Virus (JCV) has the ability to induce multiple types of brain
tumors in experimental animal models. On a molecular level, JCV
can bind to and inactivate b-catenin as well as regulate key
modulators of oncogenesis, including the IGF-IR and p53
pathways [6,29,30]. In this study, we have shown that T-antigen
is downregulated by glucose deprivation in multiple types of JCV-
transformed cell lines and that this downregulation is a product of
glucose deprivation-mediated AMPK activation (Figure 8). Since
JCV T-antigen may interact with multiple members of the AMPK
pathway, it is likely that signaling through this pathway may alter
the stability of T-antigen protein, leading to subsequent degrada-
tion. Given findings of AMPK-activated cell cycle arrest in the G1
phase of the cell cycle, our data support the possibility that T-
antigen expression status may be linked to the phase of the cell
cycle. Our data indicate that T-antigen-expressing BsB8 cells
preferentially accumulate in the G2 phase of the cell cycle and that
deviation from this cell cycle phase, which occurs through the
process of glucose deprivation, induces T-antigen downregulation.
Interestingly, this downregulation is lost if AMPK activation is
inhibited, which causes G2 re-accumulation during glucose
deprivation, further connecting T-antigen expression to the G2
phase. These findings are supported by publications demonstrat-
ing that several viruses preferentially induce G2 cell cycle arrest,
such as HIV [31], HBV [32], and HPV [33]. Our results from
studying the AMPK pathway are reinforced by the observation
that T-antigen-expressing BsB8 cells exhibit significantly greater
cyclin B1 expression and a greater percentage of cells in the G2
phase than the similar T-antigen non-expressing cells. In the
context of glucose deprivation, T-antigen preferential arrest in the
G2 phase may help to prevent G1 arrest and G1-mediated
apoptosis, processes that can occur with a multitude of other cell
stressors, such as UV exposure, hypoxia, and various chemother-
apeutic agents. Therefore, cells expressing T-antigen may resist
cytotoxic processes that are activated during the G1 phase.
Though T-antigen has previously been shown to induce tumor
cell growth through regulation of multiple tumor suppressor
pathways, these studies implicate T-antigen in the metabolic
regulation of medulloblastoma cells. We observed that glucose
deprivation reduced ATP levels in all cells tested, but BsB8 cells
exhibited lower basal levels of ATP and less change in ATP levels
during glucose starvation than Bs1a or Bs1f cells. Therefore, it
appears that BsB8 cells produce less ATP under normal
conditions, perhaps due to other pathways that fuel the metabolic
needs of these cells. Alternatively, BsB8 cells may have evolved
ways to develop more efficient pathways of energy utilization so
that periods of starvation do not as greatly affect their growth as T-
antigen non-expressing cells. Enhanced metabolic efficiency may
also help to reduce the production of ROS, which do not
accumulate to as great an extent in BsB8 as Bs1a and Bs1f cells.
Our findings of reduced hexokinase 2 expression levels in BsB8
cells relative to Bs1a and Bs1f cells during glucose deprivation
indicate that BsB8 cells may therefore import less glucose under
starvation conditions but may actually upregulate this pathway
under control conditions, as evidenced by results in HJC-2 cells. In
this sense, BsB8 cells may be less glucose-dependent under
conditions of cell stress than their T-antigen non-expressing
counterparts, which undergo more rapid cell death when their
critical energy source is depleted.
Given our observations that T-antigen-expressing cells exhibit
increased expression of transaldolase-1 (TALDO1) but similar
levels of glucose 6-phosphate dehydrogenase (G6PDH) and the
M2 isoform of pyruvate kinase (PKM2), T-antigen may simulta-
neously support both glycolysis and the pentose phosphate
pathway. This scenario has been shown for SV40-transformed
cells, which demonstrate redistribution of membrane glucose
transporters [34], increases in aerobic glycolysis [35], and
increases in the activity of the transaldolase enzyme [36],
indicating that SV40 is capable of regulating glycolytic precursors
and the redox status maintained by pentose phosphate NADPH
Figure 6. T-antigen is downregulated by glucose deprivation through specific glycolytic pathways and influences the glycolytic
enzyme expression profile of medulloblastoma cells. BsB8 cells were treated with the indicated doses of 2-deoxy-D-glucose (2-DG) (A),
oxamate (B), 6-aminonicotinamide (6-AN) (C), and oxythiamine (D) for 24 hours, and T-antigen expression was measured by western blot. E. Bs1a,
Bs1f, and BsB8 cells were exposed to glucose deprivation for 24 hours, and glycolytic enzyme expression was measured by western blot. F. HJC-2 cells
were transduced with lentivirus expressing Large T-antigen, scrambled shRNA, or were non-transduced and then exposed to glucose deprivation for
16 hours. Glycolytic enzyme expression was measured by western blot. G. Quantification of HEK2 expression relative to Grb2 in F. C, control; GD,
glucose deprivation.
doi:10.1371/journal.pone.0035054.g006
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allow the maintenance of elevated ATP production to fulfill the
needs of cells undergoing metabolic stress. On the other hand,
enhanced TALDO1 expression could also rapidly deplete pentose
phosphate intermediates and NADPH, thereby shifting more
glucose 6-phosphate towards this pathway to sustain NADPH for
reducing equivalents. The net effect of T-antigen would then be
the acceleration of ATP production with concomitant mainte-
nance of NADPH levels to counteract resultant ROS production,
a complement of features that would greatly enhance the
malignant potential of tumor cells.
The regulation of T-antigen expression by glycolytic inhibition
also highlights the significant impact of viral oncoproteins on
glycolytic metabolism. Many oncogenic viruses, including hepatitis
C virus (HCV), human T-lymphotropic virus type 1 (HTLV-1),
and human papilloma virus (HPV), have been implicated in
alterations in glucose transport and glycolytic enzyme expression
and activity [37–39]. In addition, similar results with glycolytic
inhibition have been demonstrated with HPV E6/E7 proteins,
Figure 7. JCV T-antigen is downregulated by glucose deprivation in ex vivo glioblastoma xenograft slice cultures. A. HJC-2 brain
xenografts were sectioned and cultured in vitro and were then treated with control medium or glucose deprivation, with and without rescue from
glucose deprivation by subsequent incubation in control medium, or were untreated for various time-points and were harvested for whole tissue
lysates. Subsequently, western blot analysis for T-antigen expression was performed. B. Hematoxylin and eosin (H&E) staining as well as
immunohistochemical analysis for T-antigen expression were performed in tissue samples obtained from the xenograft slice cultures described in A.
GD, glucose deprivation.
doi:10.1371/journal.pone.0035054.g007
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that flux through this pathway may be responsible for the
expression of HPV-targeted transcription factors [40] Further-
more, since 2-DG induces a reduction in viral-cell and cell-cell
fusion [41,42], this compound may also be protective against JCV
infection, reactivation, and potentially JCV-associated malignan-
cies. 2-DG has also been indicated for the treatment of
glioblastoma [43] and other advanced solid malignancies and
synergizes with compounds used to treat virus-derived cancers,
such as carboplatin and paclitaxel [44–46]. Therefore, 2-DG in
combination with currently approved chemotherapeutic regimens
may be a useful therapeutic compound for the treatment of JCV-
associated brain tumors.
Regulation of glucose metabolism continues to represent one of
the most significant alterations in tumor cells as compared to
normal cells. By increasing production of ATP and at the same
time maintaining NADPH equivalents, tumor cells have evolved
pathways to rapidly proliferate while avoiding many of the
negative consequences of such uninhibited growth. In this study,
we show that JC Virus T-antigen is downregulated by glucose
deprivation through AMPK-dependent pathways, which also
regulates cell cycle control under these conditions. Additionally,
we indicate a new potential role for T-antigen in the regulation of
the metabolic profile of tumor cells, which may have implications
for human brain tumors that exhibit T-antigen expression. By
better understanding the mechanism of T-antigen-mediated
glycolytic regulation, it may be possible to develop novel
therapeutics that would target T-antigen in human tumors, which
could potentially influence both initial transforming events as well
as continued growth in the midst of metabolic stress signals within
the tumor microenvironment.
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Figure 8. Mechanism and significance of metabolic signaling pathways affected by the presence of JCV T-antigen. JCV T-antigen is
downregulated by glucose deprivation in an AMPK-dependent manner. During periods of glucose deprivation, T-antigen inhibits AMPK
phosphorylation, which prevents the induction of reactive oxygen species (ROS) and subsequent cytotoxicity. Additionally, T-antigen relieves AMPK-
mediated cyclin B1 and cyclin A inhibition, leading to decreased G1 arrest. Glucose deprivation induces both enhanced glycolytic flux to maintain
high levels of ATP production as well as enhanced pentose phosphate pathway activation to supply reducing equivalents in the form of reduced
nicotinamide adenine dinucleotide phosphate (NADPH) to counteract ROS production produced by glycolysis. T-antigen upregulates transaldolase-1
(TALDO1) expression to shift intermediates from the pentose phosphate pathway towards glycolysis to enhance ATP production and also prevents
hexokinase 2 (HK2) upregulation during glucose deprivation. (HK2, hexokinase; G6PDH, glucose 6-phosphate dehydrogenase; 6-PGDH, 6-
phoshogluconate dehydrogenase; TKTL, transketolase; PKM2, pyruvate kinase M2; LDH, lactate dehydrogenase; 2-DG, 2-deoxyglucose; 6-AN, 6-
aminonicotinamide; OT, oxythiamine).
doi:10.1371/journal.pone.0035054.g008
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